Evaluation of the Hepa Wash®treatment in pigs with acute liver failure
Open Access
- 13 May 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Gastroenterology
- Vol. 13 (1), 1-10
- https://doi.org/10.1186/1471-230x-13-83
Abstract
Mortality of patients with acute liver failure (ALF) is still unacceptably high. Available liver support systems are still of limited success at improving survival. A new type of albumin dialysis, the Hepa Wash® system, was newly introduced. We evaluated the new liver support system as well as the Molecular Adsorbent Recycling System (MARS) in an ischemic porcine model of ALF. In the first study animals were randomly allocated to control (n=5) and Hepa Wash (n=6) groups. In a further pilot study, two animals were treated with the MARS-system. All animals received the same medical and surgical procedures. An intraparenchymal intracranial pressure was inserted. Hemodynamic monitoring and goal-directed fluid therapy using the PiCCO system was done. Animals underwent functional end-to-side portacaval shunt and ligation of hepatic arteries. Treatment with albumin dialysis was started after fall of cerebral perfusion pressure to 45 mmHg and continued for 8 h. All animals in the Hepa Wash group survived the 13-hour observation period, except for one that died after stopping treatment. Four of the control animals died within this period (p=0.03). Hepa Wash significantly reduced impairment of cerebral perfusion pressure (23±2 vs. 10±3 mmHg, p=0.006) and mean arterial pressure (37±1 vs. 24±2 mmHg, p=0.006) but had no effect on intracranial pressure (14±1 vs. 15±1 mmHg, p=0.72). Hepa Wash also enhanced cardiac index (4.94±0.32 vs. 3.36±0.25 l/min/m2, p=0.006) and renal function (urine production, 1850 ± 570 vs. 420 ± 180 ml, p=0.045) and eliminated water soluble (creatinine, 1.3±0.2 vs. 3.2±0.3 mg/dl, p=0.01; ammonia 562±124 vs. 1382±92 μg/dl, p=0.006) and protein-bound toxins (nitrate/nitrite 5.54±1.57 vs. 49.82±13.27 μmol/l, p=0.01). No adverse events that could be attributed to the Hepa Wash treatment were observed. Hepa Wash was a safe procedure and improved multiorgan system failure in pigs with ALF. The survival benefit could be the result of ameliorating different organ functions in association with the detoxification capacity of water soluble and protein-bound toxins.Keywords
This publication has 36 references indexed in Scilit:
- Does renal replacement therapy increase mortality in the ICU?Critical Care, 2011
- A Model of Ischemic Isolated Acute Liver Failure in Pigs: Standardizing Monitoring and TreatmentEuropean Surgical Research, 2010
- The treatment of acute liver failure with fractionated plasma separation and adsorption system: Experience in 85 applicationsJournal of Clinical Apheresis, 2010
- Effective Bilirubin Reduction by Single‐Pass Albumin Dialysis in Liver FailureArtificial Organs, 2009
- A Case-Control Study of Single-Pass Albumin Dialysis for Acetaminophen-Induced Acute Liver FailureBlood Purification, 2009
- Single pass albumin dialysis (SPAD) in fulminant Wilsonian liver failure: a case reportPediatric Nephrology, 2008
- Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008Critical Care Medicine, 2007
- Improvement of hepatorenal syndrome with extracorporeal albumin dialysis mars: Results of a prospective, randomized, controlled clinical trialLiver Transplantation, 2003
- Systemic hemodynamic effects of treatment with the molecular adsorbents recirculating system in patients with hyperacute liver failure: A prospective controlled trialLiver Transplantation, 2003
- Circulatory, Respiratory, Cerebral, and Renal Derangements in Acute Liver Failure: Pathophysiology and ManagementSeminars in Liver Disease, 1996